Total Return chart Myriad Genetics, Inc.

Stocks

Real-time Estimate Cboe BZX 03:36:06 29/10/2026 HKT			5-day change	1st Jan Change
6.580 ^USD	+4.61%		+18.40%	+7.24%

10-22	Myriad Genetics Says New Results Show Potential of MRD Detection in Colorectal, Pancreatic Cancers	MT
10-22	Myriad Genetics, Inc. Releases New MONSTAR-SCREEN-3 Data Demonstrating The Potential Of Ultra-Sensitive MRD Detection In Colorectal And Pancreatic Cancers	CI

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.